Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology

Clinical Chemistry

Volumn 44, Issue 11, 1998, Pages 2360-2362

  Clark, Zoe E ^a   Bowen, Derrick J ^a   Whatley, Sharon D ^a   Bellamy, Michael F ^a   Collins, Peter W ^a   McDowell, Ian F W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID;

AMINO ACID SYNTHESIS; ARTICLE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; FOLIC ACID DEFICIENCY; GENE DELETION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NEURAL TUBE DEFECT; POLYACRYLAMIDE GEL ELECTROPHORESIS; RISK ASSESSMENT;

ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEAT; HETERODUPLEX ANALYSIS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTAGENESIS, SITE-DIRECTED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMERASE CHAIN REACTION;

EID: 0031757073     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease-probable benefits of increasing folic acid intake. JAMA 1995;274:1049-57.
2. Wilcken DE. MTHFR 677C→T mutation, folate intake, neurl tube defect, and risk of cardiovascular disease. Lancet 1997;388:603-4.
3. Goyette P, Sumner JS, Milos R, Duncan AN, Rasanblatt DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Net Geriet 1994;7:195-200.
4. Kang SS, Passen EL, Ruggie N, Wong APWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-9.
5. Jacques PF, Bostom AG, William RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylene tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
6. Frosst P, Blom HL, Milos R, Goyette P, Sheppard CA, Matthews TH, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat Genet 1995;10:111-3.
7. Wood N, Bidwell J. Genetic screening and testing by induced heteroduplex formation. Electrophoresis 1996;17:247-54.
8. Bowen DJ, Standen GR, Granville S, Bowley S, Wood NAP, Bidwell J. Genetic diagnosis of factor V Leiden using heteroduplex technology. Thromb Haemost 1997;77119-22.
9. Ankri A, Bonnefont JP, Chadefauz-Vekemans B, Mostefa AK, Aupetit J, Couty MC, et al. The 677C→T mutation in the methylene tetrahydrofolate reduc tase gene is not related to hyperhomocysteinaemia in thrombotic disease [Abstract]. Thromb Haemost Suppl 1997:P2160.
10. Harmon DL, Woodside JV, Yarnell JWG, McMaster D, Young IS, McCrum EE, et al. The common thermolabile variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med 1996;89:571-7.
11. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG. et al. Thermolabile methylene tetrahydrofolate reductase in coronary artery disease. Circulation 1997;96:2573-7.